Research Desk Line-up: Edwards Lifesciences Post Earnings Coverage
LONDON, UK / ACCESSWIRE / October 27, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Zimmer Biomet Holdings, Inc. (NYSE: ZBH) (“Zimmer Biomet”), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=ZBH. The Company announced on October 25, 2017, that it has officially launched the Vitality®+ and the Vital™ Spinal Fixation Systems in the United States at the 2017 North American Spine Society (NASS) Annual Meeting. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Medical Appliances & Equipment industry. Pro-TD has currently selected Edwards Lifesciences Corporation (NYSE: EW) for due-diligence and potential coverage as the Company reported on October 24, 2017, its financial results for Q3 which ended on September 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Edwards Lifesciences when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ZBH; also brushing on EW. Go directly to your stock of interest and access today's free coverage at:
About Vitality®+ Spinal Fixation System
The Vitality®+ Spinal Fixation System is a thoracolumbar and sacroiliac fixation system designed to aid in the surgical correction of several types of spinal conditions. The system consists of Vitality+ POWER for simple, controlled pedicle preparation and pedicle screw insertion; Vitality+ PSO for optimal pedicle subtraction osteotomy and vertebral column resection procedures; and Vitality+ HOOKS with an extensive array of additional fixation options. These devices are indicated as an adjunct to fusion for degenerative disc disease, spondylolisthesis, trauma, deformities or curvatures, tumor, stenosis, pseudo-arthrosis, and failed previous fusions.
For degenerative thoracolumbar procedures, Vitality®+ is available in a two-kit pedicle screw instrument configuration. This system is intended for the treatment of severe spondylolisthesis of the L5-S1 vertebra in skeletally mature patients receiving fusion by autogenous bone graft and having implants attached to the lumbosacral spine and/or ilium with a removal of the implant after attainment of a solid fusion.
About Vital™ Spinal Fixation System
The Vital™ Spinal Fixation System is a subsystem of the Vitality®+ Spinal Fixation System. The minimized two-kit configuration includes all pertinent instruments required for degenerative spine surgeries with an easy-to-follow color-coded tray layout. The upgraded Vital™ screws incorporates T27 hexalobe drive feature, one of the largest drive standards in the industry, designed to provide 30% more strength than the T25 hexalobe. The Vital™ Spinal Fixation System's dual lead screws require fewer revolutions for insertion, as they can be inserted twice as fast as comparable single lead screws, without sacrificing pull-out strength.
510(k) Clearance for Pedicle Preparation and Screw Insertion Under Power
The Launch of Vitality+ POWER is followed by Zimmer Biomet's 510(k) clearance for pedicle preparation and screw insertion under power in September 2017. The Department of Health & Human Services approved to legally market the Vitality®+ Spinal Fixation System and Vitality®+ Power Instrument System, subject to the general controls provisions of the Act.
The Vitality®+ Power Instrument System includes instrumentation to be used with power for the preparation of the pedicle and ilium and insertion of Vitality®+ Spinal Fixation System screws.
Zimmer Biomet Launched Avenue® T TLIF Cage with Integrated VerteBRIDGE® Plating in the US
On October 02, 2017, Zimmer Biomet officially launched the Avenue® T TLIF Cage in the United States. The Avenue® T TLIF Cage advances posterior lumbar cage technology by incorporating VerteBRIDGE® plating, which facilitates the simplified cage insertion and zero-profile, intradiscal fixation through a direct, minimally invasive surgical approach. Zimmer Biomet is the first Company to offer a suite of lumbar cages with integrated fixation for every fusion approach.
About Zimmer Biomet Holdings, Inc.
Founded in 1927, Zimmer Biomet is the world's most trusted brand for personalized bone and joint healthcare solutions. As a leading innovator in musculoskeletal healthcare, the Company offers a complete portfolio of products for joint reconstruction, bone and skeletal repair, sports medicine, spine, and dental reconstruction. Zimmer Biomet is headquartered in Warsaw, Indiana.
Last Close Stock Review
On Thursday, October 26, 2017, the stock closed the trading session at $121.00, slightly falling 0.38% from its previous closing price of $121.46. A total volume of 1.18 million shares have exchanged hands. Zimmer Biomet's stock price advanced 4.09% in the last one month and 1.13% in the past six months. Furthermore, since the start of the year, shares of the Company have surged 17.25%. The stock is trading at a PE ratio of 34.53 and has a dividend yield of 0.79%. The stock currently has a market cap of $24.37 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily